The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy by evaluating area under the curve (AUC) and maximum plasma concentration (Cmax) exposure. The Phase 2 portion of the study is to assess the efficacy of ASTX727 and venetoclax when given in combination and to evaluate potential PK interactions. Phase 2 will follow the same overall study design as Phase 1.
Est. Enrollment: 124 participants
Study Start Date: Feb 09, 2021
Study Completion Date: Jul 01, 2024
Age: 18+ years
Gender: All
Contact Us
A member of our team would love to assist you.
How Clinical Trials Work (800) 930-5159 Email usSubscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811